Asset Prioritization

Expanding Into Asia-Pacific: Life sciences opportunities and strategies for success
Objective :

Asset Prioritization Analysis to provide Strategic direction to the client in Atrial Fibrillation space along with Identification of best possible asset to support client’s future development and licensing needs.

Problem Statement:

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

Our Methodology:
  • Technology Assessment
  • Company Assessment
  • Commercial Assessment
  • Clinical Assessment
  • Primary Assessment
  • Matrix Analysis
  • Best Possible Asset Identified
Results:
  • Matrix Analysis positioned the top 20 companies researched.
  • The client could assess the Top companies which would effectively fit their strategic needs and objectives (the TARGET quadrant).
  • Insights into market trends for different candidates the company is developing and helping to prioritise the products.

Related Insights

Due Diligence
Due Diligence

A medium pharmaceutical client with capabilities in novel formulations was involved in a deal with a manufacturing company for commercial-scale manufacturing of the client’s therapies. [...]

View Case
Competitive Intelligence
Competitive Intelligence

A large client based in Europe involved DelveInsight to assist in assessing counter-intelligence strategies for them, after evaluation of their level of leakiness among middle and high-level employees. [...]

View Case
Competitive Benchmarking
Competitive Benchmarking

A large pharmaceutical client based in Europe involved DelveInsight to identify patient advocacy strategies of companies operating in the Pharma sector of the European Union, to benchmark their efforts against their competitors. [...]

View Case

Fill the form to download the case study

I consent to DelveInsight gathering details provided via this form. Check our Privacy Policy to know more.